Cryoport, Inc. ( CYRX ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief Administrative Officer Mark W. Sawicki - Senior VP & Chief Scientific Officer Thomas Heinzen - Vice President of Corporate Development & Investor Relations Conference Call Participants Todd Fromer - Kanan, Corbin, Schupak & Aronow, Inc. Kyle Crews - UBS Investment Bank, Research Division David Saxon - Needham & Company, LLC, Research Division Puneet Souda - Leerink Partners LLC, Research Division Matthew Stanton - Jefferies LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division David Larsen - BTIG, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Presentation Operator " Jerrell Shelton Chairman, President & CEO " Robert Stefanovich Senior VP, CFO, Treasurer & Chief Administrative Officer " Mark W.
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.02 per share a year ago.
Cryoport, Inc. (NASDAQ:CYRX ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Jerrell W. Shelton - Chairman, President & CEO Mark W.
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.33 per share a year ago.
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CryoPort, Inc. (CYRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CYRX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Does CryoPort, Inc. (CYRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
CryoPort (CYRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 81.4% in CryoPort (CYRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The mean of analysts' price targets for CryoPort (CYRX) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.43 per share a year ago.
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.